The US FDA has accepted a biologics license application for ivonescimab in combination with chemotherapy for the treatment of patients with EGFR-mutant non-small cell lung cancer. The application seeks approval for use in patients who have progressed after tyrosine kinase inhibitor therapy. The specifics of the intended patient population and treatment regimen are somewhat unclear, with descriptions varying as second-line or later treatment or post-TKI progression.